Literature DB >> 27578123

Clinical and genetic features of 3 patients with familial chylomicronemia due to mutations in GPIHBP1 gene.

Claudio Rabacchi1, Sergio D'Addato2, Silvia Palmisano2, Tiziano Lucchi3, Stefano Bertolini4, Sebastiano Calandra5, Patrizia Tarugi6.   

Abstract

BACKGROUND: Familial chylomicronemia is a recessive disorder that may be due to mutations in lipoprotein lipase (LPL) and in other proteins such as apolipoprotein C-II and apolipoprotein A-V (activators of LPL), GPIHBP1 (the molecular platform required for LPL activity on endothelial surface), and LMF1 (a factor required for intracellular formation of active LPL).
METHODS: We sequenced the familial chylomicronemia candidate genes in 2 adult females presenting long-standing hypertriglyceridemia and a history of acute pancreatitis.
RESULTS: Both probands had plasma triglyceride >10 mmol/L but no mutations in the LPL gene. The sequence of the other candidate genes showed that one patient was homozygous for a novel missense mutation p.(Cys83Arg), and the other was homozygous for a previously reported nonsense mutation p.(Cys 89*), respectively, in GPIHBP1. Family screening showed that the hypertriglyceridemic brother of the p.(Cys83Arg) homozygote was also homozygous for this mutation. He had no history of pancreatitis. The p.(Cys83Arg) heterozygous carriers had normal triglyceride levels. The substitution of a cysteine residue in the Ly6 domain of GPIHBP1 is predicted to abolish one of the disulfide bridges required to maintain the structure of GPIHBP1. The p.(Cys89*) mutation results in a truncated protein devoid of function.
CONCLUSIONS: Both mutant GPIHBP1 proteins are expected to be incapable of transferring LPL from the subendothelial space to the endothelial surface.
Copyright © 2016 National Lipid Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Familial chylomicronemia; Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPIHBP1); Hypertriglyceridemia; Pancreatitis

Mesh:

Substances:

Year:  2016        PMID: 27578123     DOI: 10.1016/j.jacl.2016.03.009

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  12 in total

1.  GPIHBP1 autoantibodies in a patient with unexplained chylomicronemia.

Authors:  Xuchen Hu; Geesje M Dallinga-Thie; G Kees Hovingh; Sandy Y Chang; Norma P Sandoval; Tiffany Ly P Dang; Isamu Fukamachi; Kazuya Miyashita; Katsuyuki Nakajima; Masami Murakami; Loren G Fong; Michael Ploug; Stephen G Young; Anne P Beigneux
Journal:  J Clin Lipidol       Date:  2017-06-13       Impact factor: 4.766

2.  An LPL-specific monoclonal antibody, 88B8, that abolishes the binding of LPL to GPIHBP1.

Authors:  Christopher M Allan; Mikael Larsson; Xuchen Hu; Cuiwen He; Rachel S Jung; Alaleh Mapar; Constance Voss; Kazuya Miyashita; Tetsuo Machida; Masami Murakami; Katsuyuki Nakajima; André Bensadoun; Michael Ploug; Loren G Fong; Stephen G Young; Anne P Beigneux
Journal:  J Lipid Res       Date:  2016-08-05       Impact factor: 5.922

Review 3.  Chylomicronemia from GPIHBP1 autoantibodies.

Authors:  Kazuya Miyashita; Jens Lutz; Lisa C Hudgins; Dana Toib; Ambika P Ashraf; Wenxin Song; Masami Murakami; Katsuyuki Nakajima; Michael Ploug; Loren G Fong; Stephen G Young; Anne P Beigneux
Journal:  J Lipid Res       Date:  2020-09-18       Impact factor: 5.922

Review 4.  GPIHBP1 and Lipoprotein Lipase, Partners in Plasma Triglyceride Metabolism.

Authors:  Stephen G Young; Loren G Fong; Anne P Beigneux; Christopher M Allan; Cuiwen He; Haibo Jiang; Katsuyuki Nakajima; Muthuraman Meiyappan; Gabriel Birrane; Michael Ploug
Journal:  Cell Metab       Date:  2019-07-02       Impact factor: 27.287

Review 5.  Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia.

Authors:  Jan Borén; Marja-Riitta Taskinen; Elias Björnson; Chris J Packard
Journal:  Nat Rev Cardiol       Date:  2022-03-22       Impact factor: 49.421

6.  Identifying suspected familial chylomicronemia syndrome.

Authors:  Ronak Rengarajan; Peter A McCullough; Anima Chowdhury; Kristen M Tecson
Journal:  Proc (Bayl Univ Med Cent)       Date:  2018-05-21

Review 7.  New insights into apolipoprotein A5 in controlling lipoprotein metabolism in obesity and the metabolic syndrome patients.

Authors:  Xin Su; Yi Kong; Dao-Quan Peng
Journal:  Lipids Health Dis       Date:  2018-07-27       Impact factor: 3.876

8.  Large triglyceride-rich lipoproteins in hypertriglyceridemia are associated with the severity of acute pancreatitis in experimental mice.

Authors:  Yue Zhang; Wenhua He; Cong He; Jianhua Wan; Xiao Lin; Xi Zheng; Lei Li; Xueyang Li; Xiaoyu Yang; Bingjun Yu; Xunde Xian; Yin Zhu; Yuhui Wang; George Liu; Nonghua Lu
Journal:  Cell Death Dis       Date:  2019-09-30       Impact factor: 8.469

Review 9.  Evolution and Medical Significance of LU Domain-Containing Proteins.

Authors:  Julie Maja Leth; Katrine Zinck Leth-Espensen; Kristian Kølby Kristensen; Anni Kumari; Anne-Marie Lund Winther; Stephen G Young; Michael Ploug
Journal:  Int J Mol Sci       Date:  2019-06-05       Impact factor: 5.923

Review 10.  Current Diagnosis and Management of Primary Chylomicronemia.

Authors:  Hiroaki Okazaki; Takanari Gotoda; Masatsune Ogura; Shun Ishibashi; Kyoko Inagaki; Hiroyuki Daida; Toshio Hayashi; Mika Hori; Daisaku Masuda; Kota Matsuki; Shinji Yokoyama; Mariko Harada-Shiba
Journal:  J Atheroscler Thromb       Date:  2021-05-13       Impact factor: 4.928

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.